Navigation Links
NanoBio Corporation Announces Positive Phase 1 Clinical Results for,Topical Treatment for Onychomycosis

ANN ARBOR, Mich., May 22, 2007 /PRNewswire/ -- NanoBio Corporation, a biopharmaceutical company developing novel products for the treatment and prevention of serious infections, today announced positive safety data from its Phase 1 clinical study of NB-002, the company's drug candidate currently in a Phase 2 clinical trial for the topical treatment of onychomycosis.

The Phase 1 clinical study was completed in January 2007 and involved 20 subjects who received twice-daily treatments of NB-002 (0.25% or 0.5%) for 28 days. Subjects were examined on days 1, 3, 7, 14, 28 and 58 for adverse events, dermal irritation and pharmacokinetic sampling. There were no drug- related adverse events, serious adverse events or discontinuations due to adverse events in any of the subjects treated. In addition, plasma drug levels were below the limit of detection (1 ng/mL) at all time points. Based on the remarkable safety profile demonstrated in this clinical study as well as other previously conducted clinical and toxicology studies, a 42-week double-blinded Phase 2 clinical study of NB-002 was initiated by NanoBio in the first quarter of 2007.

James R. Baker, MD, NanoBio's Chairman of the Board and Chief Science Officer, commented, "A unique aspect of products derived from the company's NanoStat(TM) technology is that the treatments are not systemically absorbed and they are selectively toxic to microbes while non-irritating to the skin and mucous membranes. This Phase 1 safety data further confirms that NB-002 will offer a safe alternative to the currently available systemic products. This is a critical factor for individuals affected by onychomycosis, given approximately 95% of people with this disease remain untreated as a result of the serious toxicities associated with the oral medications on the market."

Phase 2 Clinical Study for NB-002

A randomized, double-blinded, placebo-controlled Phase 2 c
'"/>




Page: 1 2 3

Related medicine technology :

1. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
3. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
4. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:9/23/2014)... 23, 2014 In industries such ... sectors, the machines are more and more connected and ... amounts of data are being harvested by numerous sensors ... number of connected machines is estimated at several dozen ... raises the fundamental question as to how big data ...
(Date:9/23/2014)... DUBLIN , Sept. 23, 2014 ... the "Company"), a biotechnology company pioneering the manufacturing ... in emerging nations, today announced that the Depository ... for DTC,s Deposit and Withdrawal at Custodian ("DWAC") ... ("FAST") transfer agent as the distribution point.  The ...
(Date:9/23/2014)... 2014 This test can detect HIV infection if ... defined by activities that can transfer body fluids from one ... any shared needles. , An in-vitro diagnostic home-use ... HIV test works by looking for your body,s response to ... minutes, enabling patients to learn their status in a single ...
Breaking Medicine Technology:TNI BioTech, Inc. Announces Its Stock is Now DTC DWAC/FAST Eligible 2TNI BioTech, Inc. Announces Its Stock is Now DTC DWAC/FAST Eligible 3TNI BioTech, Inc. Announces Its Stock is Now DTC DWAC/FAST Eligible 4WholeHealth Products announces the release of the FDA Cleared "HIV 1&2" Rapid Diagnostic Test for Professional and Retail 2
... - Ambrilia,Biopharma Inc. (TSX:AMB), a biopharmaceutical company developing,novel ... and,cancer, held its Annual General and Special Meeting ... novel series of HIV,integrase inhibitors and recent developments ... Chairman of the Board, Mr. Frederic,Porte, and a ...
... 2007 /PRNewswire/ -- Results of the,Option (TOcilizumab ... first multinational Phase III study outside,of Japan, ... 4mg/kg,or 8mg/kg) plus methotrexate achieved a significant ... symptoms of moderate to,severe rheumatoid arthritis (RA) ...
Cached Medicine Technology:Ambrilia Highlights Encouraging Data for its HIV Integrase,Inhibitor Program and Recent Developments at Annual Meeting 2Ambrilia Highlights Encouraging Data for its HIV Integrase,Inhibitor Program and Recent Developments at Annual Meeting 3Ambrilia Highlights Encouraging Data for its HIV Integrase,Inhibitor Program and Recent Developments at Annual Meeting 4Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid,Arthritis Compared to a Current Standard of Care 2Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid,Arthritis Compared to a Current Standard of Care 3Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid,Arthritis Compared to a Current Standard of Care 4Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid,Arthritis Compared to a Current Standard of Care 5
(Date:9/23/2014)... 2014 Mirena IUD lawsuits ( http://www.themirenalawsuitcenter.com/ ... migration of the birth control device continue to mount ... According to court documents dated September 18th, an Iowa ... the IUD outside of the uterus caused the device ... is now pending in the U.S. District Court, Northern ...
(Date:9/23/2014)... 2014 The inaugural single day event ... Hotel New Otani Tokyo Gardens in Tokyo. Clinical data scientists ... and validation. , The second single day event in ... offices in Shanghai. The clinical data scientists attending this event ... figures and listings, which display data collected in clinical studies ...
(Date:9/23/2014)... Oakland, CA (PRWEB) September 23, 2014 ... Cannabis Industry Today . In its first post, the ... quickly growing and changing cannabis industry. , The cannabis ... , Colorado alone is expecting an 18-month boost of ... medicinal and adult use pot sales. And, the new ...
(Date:9/23/2014)... 23, 2014 Florida Hospital Zephyrhills ... renovated Women’s Health Center on Wednesday, September 24. ... the specially designed center offers a new level ... County. The Women’s Health Center offers comprehensive women’s ... labor and delivery through The Baby Place®, and ...
(Date:9/23/2014)... A new analysis of published studies found that ... cancer versus benign disease in regions where infections ... of lung lesions suspicious for cancer could lead ... additional potential complications and mortality. , Histoplasmosis ... that are often concentrated in bird droppings and ...
Breaking Medicine News(10 mins):Health News:Mirena IUD Lawsuit News: New Complaint Filed On Behalf of Iowa Woman Claims Mirena Migrated to Her Rectum, Bernstein Liebhard LLP Reports 2Health News:Mirena IUD Lawsuit News: New Complaint Filed On Behalf of Iowa Woman Claims Mirena Migrated to Her Rectum, Bernstein Liebhard LLP Reports 3Health News:Mirena IUD Lawsuit News: New Complaint Filed On Behalf of Iowa Woman Claims Mirena Migrated to Her Rectum, Bernstein Liebhard LLP Reports 4Health News:PhUSE Further Expands its Global Community Into the Asian Region 2Health News:Oaksterdam University Addresses "Why Quality Training Matters in a Growing Marijuana Industry" in First Blog Post 2Health News:Oaksterdam University Addresses "Why Quality Training Matters in a Growing Marijuana Industry" in First Blog Post 3Health News:Florida Hospital Zephyrhills Celebrates Grand Opening of Women’s Health Center 2Health News:Florida Hospital Zephyrhills Celebrates Grand Opening of Women’s Health Center 3Health News:Study questions accuracy of lung cancer screens in some geographic regions 2
... community-based oncology practices , , HOUSTON, June 10 ... nation,s foremost cancer treatment and research network and working with ... announces the launch of iKnowMed(TM) to ... health record (EHR) system designed by oncologists for ...
... ... $500 savings bond giveaway for expectant parents. M.A.Z.E. is dedicated to helping parents save ... ... -- Expectant parents can start investing for their child,s education with M.A.Z.E. Cord Blood Laboratories. ...
... 10 The Anthropedia Foundation, a non-profit organization with headquarters ... Switzerland, where it will host its first annual gala. The ... at Le Vieux Manoir, a five-star Relais & Chateaux Hotel ... artists, executives, doctors, scientists, and distinguished guests will enjoy a ...
... legally sell alcohol to teenagers after their sixteenth birthdays ... early age, but U.S. parents who follow this relaxed ... alcohol, should be careful -- it may increase the ... conducted by Caitlin Abar, graduate student, human development and ...
... 10 PIBH recognized 23 outstanding Pennsylvania workers and ... with disabilities, particularly in the workplace. , , ... at the Hilton Hotel in Harrisburg last night, celebrated ... day, however, PIBH honors the spirit and skills of ...
... , Havel,s partners with Canadian Hospital Specialties, to ... , , CINCINNATI, June 10 ... devices, has partnered with CHS, Canadian Hospital Specialties, ... EchoStim(R) and EchoBlock(R) Ultrasound Needles throughout Canada. , ...
Cached Medicine News:Health News:US Oncology Launches Oncology-Specific EHR to the Open Market 2Health News:US Oncology Launches Oncology-Specific EHR to the Open Market 3Health News:US Oncology Launches Oncology-Specific EHR to the Open Market 4Health News:M.A.Z.E. Cord Blood Laboratories Offers Expectant Parents The Chance To Win A $500 Savings Bond 2Health News:Anthropedia Foundation Charity Gala, Murten, Switzerland, in the Presence of HSH Prince Albert II of Monaco 2Health News:Zero tolerance alcohol policy good choice for parents 2Health News:PIBH with NFL Star Doug Flutie Recognizes 23 PA Workers with Disabilities, 21 Organizations Supporting Those with Disabilities 2Health News:PIBH with NFL Star Doug Flutie Recognizes 23 PA Workers with Disabilities, 21 Organizations Supporting Those with Disabilities 3Health News:PIBH with NFL Star Doug Flutie Recognizes 23 PA Workers with Disabilities, 21 Organizations Supporting Those with Disabilities 4Health News:PIBH with NFL Star Doug Flutie Recognizes 23 PA Workers with Disabilities, 21 Organizations Supporting Those with Disabilities 5Health News:PIBH with NFL Star Doug Flutie Recognizes 23 PA Workers with Disabilities, 21 Organizations Supporting Those with Disabilities 6Health News:Havel's Incorporated Expands Successful EchoStim(R) Ultrasound Needles into Canada 2
... groups of flexible lighting products. The first ... three different sizes 5", 10", and 15" ... the light). These lights are for use ... ,The second group of flexible lights ...
These units, though small, still offer sufficient output to ensure current is fully adjustable from 0 to 70 mA. Instruction manual, ball electrodes, battery and leads with alligator clips are include...
... two groups of flexible lighting products. The ... in three different sizes 5", 10", and ... of the light). These lights are for ... needed., ,The second group of flexible ...
Designed to be used for neuromuscular blockage monitoring. Provides for easy placement over the ulnar nerve on a patient's wrist. Dual element permits non-invasive monitoring using a single electrode...
Medicine Products: